For drug discovery teams advancing complex peptides, small molecules and new modalities, IRBM's expanded Purification and Automation Suite delivers a faster, more reliable path from synthesis to high-quality data required to drive confident decisions at every stage of the program…
The decision to advance a candidate is only as sound as the data behind it. Every PK/PD profile, every efficacy readout, every biomarker result carries weight, and that weight depends entirely on the quality of the system that generated it…
Rome, Italy — February 10, 2026 — IRBM, a leader in early drug discovery research, has announced a major scientific breakthrough with the discovery of a novel and potent allosteric inhibitor targeting the Zika virus (ZIKV) protease (NS2B-NS3). The findings,…
We’ve recently expanded our mass spectrometry and imaging capabilities with the installation of Bruker’s rapifleX® MALDI Tissuetyper®, making IRBM the first CRO in Italy to adopt this advanced MALDI-TOF/TOF platform. Incorporating this technology into IRBM’s established integrated drug discovery workflows enhances…
Prestigious bilingual publication highlights 30 standout companies shaping the future of Italian enterprise—from design and fashion to science and technology Rome, Italy – April 15, 2025 – IRBM has been selected as one of 30 companies featured in the newly…
De-Risking Target Validation with Data-Driven Genomic Insights ROME, April 3, 2025 /originally distributed by PRNewswire/– IRBM, an integrated Contract Research Organization (CRO) specializing in preclinical drug discovery, has established a comprehensive Functional Genomics Platform to support genetic target identification and validation, and…
Covalent inhibitors have become a key strategy in drug discovery, offering advantages such as prolonged target engagement, high potency, and selectivity. However, identifying high-quality covalent binders requires well-designed fragment libraries and robust screening methodologies to ensure efficient hit-to-lead progression. At…
At IRBM, we believe that scientific excellence thrives in environments where diverse perspectives are not only welcomed but embedded at every level of an organization. That belief is reflected in our numbers: 61% of our workforce are women. Approximately 50%…
On October 24, 2024, IRBM's CEO Matteo Liguori represented the organization at the G7 Ministerial Meeting on Development. This high-level event gathered Development Ministers from G7 countries, partner nations, international organizations, and business leaders to advance public health through global…
The IRBM Group Achieves EcoVadis Gold Rating: Leading the Way in Sustainability in the Life Sciences Sector At the IRBM Group, we believe that every decision we make can spark meaningful, positive change; and today, we’re proud to announce that…